We recently published that in thyroid and pancreatic cancer, inhibitors targeting MNK kinases can enhance the efficacy of BET inhibitors by suppressing a pro-survival signaling pathway initiated by cancer cells following treatment with BET inhibitors [16]. This evidence concerns the gene ATP7A and pancreatic neoplasm.